26 April, 2018
Bulletin from annual general meeting 2018 in Enzymatica AB (publ)
Enzymatica held its annual general meeting today 26 April 2018 in Lund. The meeting resolved upon the following:
Appropriation of profit/loss
The annual general meeting resolved to adopt the income statements and the balance sheets of the group and parent company and resolved to carry forward the funds available at the annual general meeting and, consequently, resolved not to distribute any dividend for the financial year 2017.
Discharge from liability for the members of the board of directors and the CEO
The annual general meeting discharged the board of directors and the CEO from liability for the financial year 2017.
Board of directors and auditor
The annual general meeting resolved to re-elect Bengt Baron, Mats K Andersson, Guðmundur Pálmason, Marianne Dicander Alexandersson, Sigurgeir Guðlaugsson and Louise Nicolin as members of the board of directors. Bengt Baron was re-elected chairman of the board.
The annual general meeting resolved to appoint Deloitte AB as auditor of the company for the period until the end of the next annual general meeting. Deloitte AB has informed that Per-Arne Pettersson will be auditor in charge.
Remuneration to the board of directors and the auditor
The annual general meeting resolved that the total fees to the board of directors will amount to SEK 1,100,000, excluding remuneration for committee work, of which SEK 350,000 will be paid to the chairman and SEK 150,000 to each of the other members elected at the annual general meeting. SEK 50,000 will be paid for work performed by the chairman of the audit committee and no remuneration will be paid to the other members. No remuneration will be paid to the members of the remuneration committee.
The annual general meeting resolved that fees to the auditor shall be paid according to approved invoice.
Guidelines for remuneration for senior executives
The annual general meeting resolved in accordance with the board of directors' proposal on guidelines for remuneration for senior executives.
Authorization of the board to issue new shares
The annual general meeting resolved to authorize the board to issue shares corresponding to not more than 10 per cent of the total number of shares in the company, with or without deviation from
the shareholders' preferential rights, with the purpose to raise new capital and to take advantage of future opportunities to attract new long-term owners of strategic importance to the company, to finance the company's growth strategy, as well as to enable the company to acquire the remaining minority shares in the subsidiary Zymetech ehf. by way of issue in kind.
For more information, please contact:
Fredrik Lindberg, CEO, Enzymatica AB
Tel: +46 (0)708-86 53 70 | Email: email@example.com
About Enzymatica AB
Enzymatica AB is a life science company that develops and sells medical devices for infection-related diseases. The products are based on a barrier technology that includes marine enzymes. The Company's first product is ColdZyme® Mouth Spray, which can prevent colds and reduce the duration of disease. The product has been launched in around ten markets. The strategy is to continue to grow by strengthening the Company's position in existing markets and expanding into new geographic markets through established partners. The company is headquartered in Lund and is listed on Nasdaq First North. For more information please visit: www.enzymatica.se.
Enzymatica's Certified Adviser is Erik Penser Bank.